Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
about
Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma.Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
P2860
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Proteasome inhibitors and IMiD ...... ple myeloma but not gain 1q21.
@en
Proteasome inhibitors and IMiD ...... ple myeloma but not gain 1q21.
@nl
type
label
Proteasome inhibitors and IMiD ...... ple myeloma but not gain 1q21.
@en
Proteasome inhibitors and IMiD ...... ple myeloma but not gain 1q21.
@nl
prefLabel
Proteasome inhibitors and IMiD ...... ple myeloma but not gain 1q21.
@en
Proteasome inhibitors and IMiD ...... ple myeloma but not gain 1q21.
@nl
P2093
P2860
P50
P356
P1476
Proteasome inhibitors and IMiD ...... ple myeloma but not gain 1q21.
@en
P2093
Anders Waage
Bart M S Heeg
Birgitte Preiss
Gösta Gahrton
Hanne E H Møller
Hong Yan Dai
Johan Lund
Karin Fahl Wader
Lill Anny Grøseth
Niels Abildgaard
P2860
P356
10.1111/EJH.12546
P577
2015-03-16T00:00:00Z